Eric Fischer is an Assistant Professor in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and the Dana-Farber Cancer Institute. He co-directs the DFCI Center for Protein Degradation. His research focuses on understanding the complex mechanisms that underlie function and regulation of multi-component ubiquitin ligases and their role in disease. His lab pursues novel avenues of therapeutic intervention based on targeting components of the ubiquitin proteasome system, such as methods of targeted protein degradation. Dr. Fischer has been recognized for his pioneering work on the structure of cereblon, the mechanism of action of thalidomide, and his contributions to targeted protein degradation.